AzTrials
AzTrials

Bipolar Disorder (BD)FOCUS BipolarNCT07622927

FOCUS Bipolar: Families Opening Conversations for Understanding Signs

An observational study of Bipolar Disorder (BD) and Bipolar Disorder I or II, run by University of Texas Southwestern Medical Center at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Bipolar disorder often runs in families, but early symptoms in youth can go unrecognized for years. This project evaluates a structured, family-centered approach to informed screening for youth ages 7-21 who have a biological parent with bipolar disorder. Read more about this study

Who is it for?
Ages 7 years and olderHealthy volunteers can take part
What is being tested?
Co-design Workshop (Observational Procedure), Alpha Testing (Observational Procedure) and Beta Testing (Observational Procedure)
How many people
200 participants
Where
1 siteUnited States
Study dates
11 Mar 2026to 31 Jul 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 7 years and older
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: The following groups are being targeted for this observational study: 1. Parents (age 18 or older) who have ever been diagnosed with bipolar disorder and have a biological child between the ages of 7-21 2. Caregivers (age 18 or older) who are primarily responsible for a child between the ages of 7-21 whose biological parent has a lifetime diagnosis of bipolar disorder 3. Youth (ages 7-21) without bipolar disorder, but has at least 1 biological parent with a lifetime diagnosis of bipolar disorder

Who may be able to join

  • Age: 18 years or older.
  • Caregiver status: The adult primarily responsible for the daily care and/or medical decisions for ≥ 6 months for a child aged 7-21 years whose biological parent has a lifetime, clinician-confirmed diagnosis of Bipolar I or II disorder.
  • Capacity and willingness to consent: Able and willing to provide informed consent.
  • Study participation: Able to comply with study procedures (e.g., co-design sessions, interviews, assessments).
  • Language: Able to read, speak, and understand English.
  • Age:
Show all 21Show fewer
  • Phase 1 (co-design) and Phase 2A (alpha testing): 13-18 years
  • Phase 2B (beta testing): 13-18 years
  • Phase 3 (screening): 7-21 years
  • Diagnosis status: Must not have a current diagnosis of Bipolar I or II disorder.
  • Parental diagnosis: Has at least 1 biological parent with a lifetime, clinician-confirmed Bipolar I or II diagnosis (as defined in Groups A and B).
  • Consent/Assent:
  • For youth aged 18-21: Able and willing to provide informed consent (verbal)
  • For youth aged 7-21: Parent/guardian/LAR able and willing to provide informed consent (verbal) and youth able to provide assent (verbal)
  • Participant ability: Able and willing to participate in study activities (e.g., co-design discussions, questionnaires, or screening assessments.
  • Language: English sufficient to comprehend study procedures and materials.
  • Criteria for Exclusion of Participants
  • A potential participant will NOT be eligible for participation in this study if any of the following criteria are met:
  • Unable to provide informed consent due to cognitive impairment or language barriers
  • Experiencing acute psychiatric instability at enrollment (e.g., acute psychosis or acute suicidality without stabilization)
  • Has a medical or psychiatric condition that, in the judgment of the Principal Investigator or study clinician, would place undue risk on the individual or interfere with standard clinical care

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site, 1 recruiting
  • UT Southwestern Medical Center

    Dallas, Texas, 75390

    Karabi Nandy, Ph.D., 214-648-9551, FOCUSBipolar@UTSouthwestern.edu

    Recruiting

Other trials in United States

About this study

Official title: A Data-Driven Approach to Early Mental Health Screening in Offspring of Parents With Bipolar Disorder

Bipolar disorder often runs in families, but early symptoms in youth can go unrecognized for years. This project evaluates a structured, family-centered approach to informed screening for youth ages 7-21 who have a biological parent with bipolar disorder.

The main questions addressed by this project are:

Read more

Whether a co-designed video decision aid improves caregiver understanding of bipolar disorder genetic risk and supports informed decisions about youth screening.

Whether remote mental health screening tools are feasible and acceptable for youth with familial risk for bipolar disorder.

Whether screening results can be used to identify early risk patterns and inform tailored follow-up recommendations.

Participants may be involved in one or more study activities, including co-design of educational decision-aid content, feedback on decision-aid prototypes, beta testing of the decision aid, and remote youth mental health screening. The study does not assign treatment and does not change existing clinical care or clinic routines.

Read the detailed description

Background and Rationale:

Bipolar disorder (BD), characterized by acute mood fluctuations between manic and depressive states, affects approximately 5.7 million adults each year in the United States and is the fourth leading cause of disability among those aged 10-24 worldwide. BD is estimated to inflict an annual economic burden of $195 billion in the United States alone. Despite its high prevalence and significant impact on both disability and the economy, BD is typically diagnosed 11-17 years after symptom emergence. This results in delayed intervention, increased morbidity, and an elevated suicide risk.

While the etiology of BD is unknown, there is substantial evidence suggesting that it is associated with genetic, epigenetic, and neurochemical factors. Heritability is well established. A child who has a biological parent with BD is at a 15-30% risk of developing the disorder, and the risk increases to 50-75% when both parents are affected. This familial risk is widely recognized and presents a compelling opportunity for preventive measures, particularly during the prodromal phase, prior to the realization of full diagnostic criteria.

Purpose:

The purpose of this research is to develop and evaluate a stakeholder-informed, scalable screening approach in a pilot feasibility study for early identification of mental health risk in youth (ages 7-21) who have a biological parent with bipolar disorder (BD). Despite well-documented genetic risk, there is currently no established protocol to support family-initiated screening in this high-risk group.

Objectives:

  1. Develop and refine a brief, co-designed video decision aid (DA) to support BD-affected adults or caregivers in making informed choices about screening their children.
  2. Evaluate the decision aid's effectiveness in improving knowledge, reducing decisional conflict, and increasing willingness to screen among caregivers.
  3. Conduct pilot mental health screenings of at-risk youth using a hybrid model combining fixed prodromal symptom items and the Computerized Adaptive Test for Mental Health (CAT-MH®) and Kiddie Computerized Adaptive Test for Mental Health (K-CAT-MH®) adaptive screeners.
  4. Create and evaluate a structured follow-up framework that stratifies screening results by risk and links them to relevant next steps in care.

Hypothesis:

The hypothesis is that a family-centered, stakeholder-designed decision aid will encourage a significant portion of BD-affected adults or caregivers to consent to their children's screening and that adaptive screening will find youth with early symptom patterns that might benefit from further monitoring or risk-stratified follow-up. The goal is not to identify all at-risk youth, but rather to assess the feasibility, acceptability, and preliminary yield of this family-informed screening model.

This hypothesis is supported by evidence that early symptoms such as mood instability, anxiety, and behavioral dysregulation often precede the onset of full syndromal BD, particularly in youth with a biological parent diagnosed with BD. However, existing early identification models are largely clinician-driven, and families often lack tools to guide screening decisions. Decision aids, which are widely used in other areas of healthcare, have been shown to improve decision quality, reduce decisional conflict, and increase knowledge - particularly in situations involving uncertainty or personal values. There is strong evidence that decision-making informed by stakeholders enhances the relevance, uptake, and ethical alignment of initiatives, particularly when engaging families on sensitive or stigmatized clinical topics. Finally, recent research has shown that remote, adaptive mental health screening is feasible in high-risk youth populations. These results collectively substantiate the rationale for the piloting of a novel, family-centered approach that integrates stakeholder-informed decision assistance with adaptive screening and structured follow-up.

Overarching Study Goal:

The long-term goal of this work is to generate a scalable, evidence-based model for early detection of psychiatric risk in youth with a familial history of BD. By fostering informed caregiver engagement and incorporating risk-stratified follow-up recommendations, this project establishes the foundation for future practice guidelines that transition the field from reactive diagnosis to preventive mental health care. This approach is comparable to those employed in other heritable conditions, such as cancer and heart disease.

Being tested
Co-design Workshop (Observational Procedure), Alpha Testing (Observational Procedure), Beta Testing (Observational Procedure), Youth Screening Pathway & Brief Follow-Up Interview (Observational Procedure)
Keywords
bipolar disorder, bipolar I, bipolar II, bipolar disorder screening
Medical subject headings
Bipolar Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Co-design Workshop (Observational Procedure)Other

    Participants in the workshop will help to co-design decision aid prototypes (short video and FAQ document) focused on early mental health screening for youth with one or more biological parents impacted by BD.

  • Alpha Testing (Observational Procedure)Other

    Participants will provide feedback on the initial version of the patient decision aid (short video and FAQ document).

  • Beta Testing (Observational Procedure)Other

    Participants will provide feedback on the refined version of the patient decision aid (short video and FAQ document).

  • Youth Screening Pathway & Brief Follow-Up Interview (Observational Procedure)Other

    Youth participants will take screening surveys for early bipolar risk detection.

Study groups in NCT07622927
Study groupRoleWhat they receive
Group A - Parent with Bipolar DisorderParents (age 18 or older) who have ever been diagnosed with bipolar disorder and have a biological child between the ages of 7-21
Receives: Other: Co-design Workshop (Observational Procedure); Other: Alpha Testing (Observational Procedure); Other: Beta Testing (Observational Procedure)
Group B - Adult CaregiverCaregivers (age 18 or older) who are primarily responsible for a child between the ages of 7-21 whose biological parent has a lifetime diagnosis of bipolar disorder
Receives: Other: Co-design Workshop (Observational Procedure); Other: Alpha Testing (Observational Procedure); Other: Beta Testing (Observational Procedure)
Group C - At-Risk YouthYouth (ages 7-21) without bipolar disorder, but has at least 1 biological parent with a lifetime diagnosis of bipolar disorder
Receives: Other: Co-design Workshop (Observational Procedure); Other: Alpha Testing (Observational Procedure); Other: Beta Testing (Observational Procedure); Other: Youth Screening Pathway & Brief Follow-Up Interview (Observational Procedure)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Decision Aid Acceptability Score

    Mean participant rating of decision aid acceptability using study-specific Likert-type items assessing clarity, balance, trustworthiness, and usefulness. Items are rated from 1 to 5, with 1 indicating strongly disagree and 5 indicating strongly agree. Higher scores indicate greater acceptability.

    Measured: 16 Months

  2. Decision Aid Usability Score

    Description:

    Mean participant rating of decision aid usability using study-specific Likert-type items assessing ease of navigation, visual clarity, and overall satisfaction. Items are rated from 1 to 5, with 1 indicating strongly disagree and 5 indicating strongly agree. Higher scores indicate greater usability.

    Measured: 16 Months

  3. Youth Screening Uptake Rate

    Percentage of eligible caregivers who consent for youth mental health screening after participation in the decision-aid workflow.

    Measured: 16 Months

  4. Youth Screening Completion Rate

    Percentage of youth participants who complete the assigned remote mental health screening battery after consent or permission and assent, as applicable.

    Measured: 16 Months

Secondary outcomes (4)
  1. Time to Complete Youth Screening

    Time in minutes required for youth participants to complete the assigned remote mental health screening battery.

    Measured: 16 Months

  2. Youth and Caregiver Post-Screening Feedback Score

    Mean post-screening feedback score from youth and caregiver surveys assessing clarity, comfort, perceived burden, and usefulness of the screening process. Items are rated from 1 to 5, with 1 indicating strongly disagree and 5 indicating strongly agree. Higher scores indicate more favorable feedback.

    Measured: 16 Months

  3. Safety Flag Rate

    Percentage of screened youth whose responses trigger the study safety protocol based on pre-specified screening thresholds.

    Measured: 16 Months

  4. Risk Stratification Category Distribution

    Percentage of screened youth assigned to each pre-specified risk category based on the fixed-item and adaptive screening algorithm. Categories may include low, moderate, or elevated risk.

    Measured: 16 Months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Jun 2026
  2. Study start11 Mar 2026
  3. Primary completion30 Jun 2027 (estimated)
  4. Study completion31 Jul 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Family based
Time perspective
Prospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07622927
Sponsor's protocol ID
STU20251974
Acronym
FOCUS Bipolar
Status last verified
May 2026
First submitted
21 Feb 2026
Last updated
3 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Bipolar Disorder (BD) and Bipolar Disorder I or II, run by University of Texas Southwestern Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 21 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 3 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Karabi Nandy, Ph.D. (214-648-4490, FOCUSBipolar@UTSouthwestern.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Decision Aid Acceptability Score (time frame: 16 Months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jun 2026; AzTrials last refreshed its copy on 26 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in